ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 573,65
-0,77%
Dow Jones
40 211,72
0,53%
DAX
18 499,97
-0,54%
Brent Oil
83,275
-1,26%
Bitcoin
63 703,40
-1,77%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
09/03/201521h12GlobeNewswire Inc.Portola Pharmaceuticals Announces Proposed Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
02/03/201523h14Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTLAPortola Pharmaceuticals Inc
02/03/201514h21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
02/03/201514h01GlobeNewswire Inc.Portola Announces Full Results From Positive Phase 3 ANNEXA(TM)-R Study Demonstrating That Andexanet Alfa Rapidly and Signifi...NASDAQ:PTLAPortola Pharmaceuticals Inc
02/03/201514h00GlobeNewswire Inc.Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2014 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
26/02/201514h00GlobeNewswire Inc.Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibi...NASDAQ:PTLAPortola Pharmaceuticals Inc
25/02/201522h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
24/02/201522h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, Ma...NASDAQ:PTLAPortola Pharmaceuticals Inc
24/02/201500h18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
13/02/201519h46Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201516h54Edgar (US Regulatory)Schedule 13g
(sc 13g/a)		NASDAQ:PTLAPortola Pharmaceuticals Inc
11/02/201500h16Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/02/201522h00GlobeNewswire Inc.Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege and Dr. Dennis Fenton, to Board of Director...NASDAQ:PTLAPortola Pharmaceuticals Inc
05/02/201522h06GlobeNewswire Inc.Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis in Phase 3 APEX Study; Trial Continues as Plan...NASDAQ:PTLAPortola Pharmaceuticals Inc
26/01/201517h52GlobeNewswire Inc.Portola Pharmaceuticals Announces Dr. Robert Califf Retires From the Board of Directors to Accept Position as Deputy Commissi...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/01/201514h00GlobeNewswire Inc.Portola Pharmaceuticals Initiates Phase 4 Study to Support Accelerated Approval of Andexanet Alfa -- Its Breakthrough-Designa...NASDAQ:PTLAPortola Pharmaceuticals Inc
09/01/201514h00GlobeNewswire Inc.Portola Announces Phase 3 ANNEXA-R Study of Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) (rivaroxaban) Met Primary Endpo...NASDAQ:PTLAPortola Pharmaceuticals Inc
06/01/201522h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Webcast of Corporate Presentation on January 12, 2015NASDAQ:PTLAPortola Pharmaceuticals Inc
31/12/201415h52Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:PTLAPortola Pharmaceuticals Inc
03/10/201412h08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/10/201422h09Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:PTLAPortola Pharmaceuticals Inc
06/08/201423h27Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
30/07/201422h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 20...NASDAQ:PTLAPortola Pharmaceuticals Inc
10/07/201418h12Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTLAPortola Pharmaceuticals Inc
07/07/201420h10GlobeNewswire Inc.Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inh...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/06/201422h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
11/06/201414h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxapari...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/05/201423h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Two Presentations of Data on Cerdulatinib, an Oral Dual Syk/JAK Inhibitor, at 2014 ASCO Ann...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/05/201422h02GlobeNewswire Inc.Portola Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
12/05/201414h00GlobeNewswire Inc.Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor X...NASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

LSE
TOPE
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés